Higher-order cross­overs [Power / Sample Size]

posted by sweiner – 2020-01-22 20:22 (478 d 19:21 ago) – Posting: # 21081
Views: 3,302

I would like to obtain an advice on BE study sample size estimation.
Let’s say, we are planning a 2x2 crossover study for BE, and the intra-subject coefficient of variation for our test compound, from a prior study, is 23%. The assumed geometric mean ratio is 1.00, alpha is 0.05, equivalence limits are 80%-125%, and we desire power of 80%. These criteria result in an overall sample size of 20 subjects, or 10 per sequence.
Subsequently, we want to add 2 extra dose levels of our test drug, resulting in a 4x4 crossover trial. Let’s assume that %CV and GMR are not changing, as no further data is available. For this new scenario, is it appropriate to: 1) use the original sample size of N=20 and simply divide it over 4 sequences (5 per sequence), or 2) take the original per sequence sample size of 10 and multiply by 4 to get 40 subjects overall needed? In either case 1) or 2), is there a supporting reference you can provide?

Edit: Category and subject line changed; see also this post #1 and #2[Helmut]

Complete thread:

 Admin contact
21,462 posts in 4,487 threads, 1,514 registered users;
online 4 (0 registered, 4 guests [including 4 identified bots]).
Forum time: Saturday 16:44 CEST (Europe/Vienna)

By all means let’s be open-minded, but not so open-minded
that our brains drop out.    Richard Dawkins

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz